Types of studies Sample Clauses

Types of studies. (i) Pharmaco- kinetics studies. Groups A through F shall be used to determine the kinetics of absorption of the test substance. In animal subjects administered the test substance intravenously (i.e., Group A), the concentration of test substance in blood and excreta shall be measured following administration. In animal subjects administered the test sub- stance by the inhalation and dermal routes (i.e., Groups B through F), the concentration of test substance in blood shall be measured at selected time intervals during and following the exposure period. In animal subjects ad- ministered the test substance by the inhalation route (i.e., Groups B, C, and F) the concentration of test substance in excreta shall be measured following exposure. In animal subjects adminis- tered the test substance by the dermal route (i.e., Groups D and E) the con- centration of test substance in excreta shall be measured during and following exposure. These measurements allow calculation of uptake, half lives, and clearance. In addition, in the groups administered the test substance by in- halation (i.e., Groups B, C, and F), the concentration of test substance in the exposure chamber air shall be meas- ured at selected time intervals during the exposure period.
View SourceView Similar (10)
Types of studies. (i) Pharmaco- kinetics studies—
View SourceView Similar (8)
Types of studies. (i) Pharmaco- kinetics studies. Groups A through F shall be used to determine the kinetics of absorption of the test substance. In groups administered the substance by intravenous or oral routes, (i.e., Groups A, B, C, F), the concentration of radio- activity in blood and excreta including expired air shall be measured following administration. In groups administered the substance by the inhalation route (i.e., Groups D and E), the concentra- tion of radioactivity in blood shall be measured at selected time intervals during and following the exposure pe- riod. In the groups administered the substance by inhalation (i.e., Groups D and E), the concentration of radioac- tivity in excreta (including expired air) shall be measured at selected time in- tervals following the exposure period. In addition, in the groups administered the substance by inhalation, the con- centration of test substance in inspired air shall be measured at selected time intervals during the exposure period.
View SourceView Similar (4)
Types of studies. (i) Pharmacokinet- ics studies—
View SourceView Similar (2)
Types of studies. (a) From time to time MFI and HBI may agree to joint multi-client studies using the internet ("JV MULTI-CLIENT STUDY(IES)"). (b) HBI may choose to do multi-client studies for its own account using the internet ("HBI MULTI-CLIENT STUDY(IES)"). Rights of HBI to conduct HBI Multi-Client Studies alone or with other Persons, or to license or rent use of the HBI Database to customers or clients in connection with multi-client studies being performed by them, are not covered by this Agreement and HBI may conduct the same independent of and without regard to its relationship with MFI except as otherwise expressly provided herein. (c) MFI may choose to do multi-client studies for its own account using the internet ("MFI MULTI-CLIENT STUDY(IES)"). MFI Multi-Client Studies may be conducted by MFI alone or with other Persons, provided however, that MFI shall use HBI services covered by Use Fees, Access Fees if the HBI Database is used rather than MFI Names, and Survey Fees in connection with all such MFI Multi-Client Studies subject to the terms of this Agreement.
View SourceView Similar (2)
Types of studies. Studies that have a) developed/described; or b) tested prospectively at least one standardized model that consists of a systematic method of appraising risk of harm posed to a child, within a European or UK context, and assisting case decision-making [or a model, developed elsewhere, which could potentially be used in the UK].
View Source
Types of studies. For the assessment of effectiveness; good quality systematic reviews of experimental and observational studies, randomised controlled trials, controlled non-randomised studies, controlled and uncontrolled before and after studies, cross-sectional studies, cohort studies, case-control studies and ecological studies. For the assessment of cost-effectiveness; economic evaluations conducted alongside trials, modelling studies and analyses of administrative databases. Only full economic evaluations that compare two or more options and consider both costs and consequences (including cost-effectiveness, cost-utility and cost-benefit analyses) will be eligible. For the review of qualitative literature; studies of any qualitative design will considered for inclusion, for example, ethnographic studies, studies that use a phenomenological or grounded theory approach, or participatory action research. For studies based on mixed methods research, both the qualitative and quantitative elements will be screened for inclusion. Interventions involving the distribution of needles, syringes and other injection equipment (e.g. filters, mixing containers and sterile water) will be eligible. As in the original reviews, needle and syringe exchange programmes (NSPs) are defined as the supply of needles, syringes and other injection equipment for the preparation and consumption of drugs.
View Source
Types of studies. All study types were included. We excluded people with intellectual disabilities and deaf blind people. Types of participants: Participants were DHH persons of any age, gender and region of origin. We excluded people with intellectual disabilities and deaf blind people. Types of interventions: Any strategy with the primary intent of improving healthcare provision for DHH. Articles on deaf education, hearing revalidation, genetic counselling, non-institutionalised mental healthcare and Deaf culture were excluded.
View Source

Related to Types of studies

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement or the Prospectus, or the results of which are referred to in the Registration Statement or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMA, Health Canada and other comparable regulatory agencies outside of the U.S. to which they are subject, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, 312, and 812; the descriptions of the results of such studies, tests and trials contained in the Registration Statement or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement or the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Scope of Collaboration As part of the collaboration, the Controllers will act as Joint Controller. The roles of the Controller and the associated tasks are specified in more detail in Appendix 1. If one party is solely responsible for a data processing operation, this party will implement all relevant data protection provisions on its own responsibility. However, such data processing procedures are not subject to this Agreement. Joint data processing and the type of Personal Data collected and processed within the framework of collaboration are specified in Appendix 1.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.